TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18202966

Group type: EXPERIMENTAL
Intervention: E2/NETA 0.1
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: E2/NETA 0.25
Number of subjects: 575

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: All groups (E2/NETA 0.1, E2/NETA 0.25, Placebo)
Number of subjects: 575
Study: 16214436

Group type: EXPERIMENTAL
Intervention: Electrocardiographic LVH
Number of subjects: 273
Study: 12171821

Group type: EXPERIMENTAL
Intervention: IV magnesium sulfate (2 grams)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 10578225

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/daily) + Hydrochlorothiazide (25 mg/daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/daily) + Indapamide (2.5 mg/daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Perindopril (4 mg/daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg/daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg/daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of P + HCT
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of P + IND
Number of subjects: 14
Study: 7788038

Group type: EXPERIMENTAL
Intervention: 60 mg sustained-release isosorbide-5-nitrate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2195346

Group type: EXPERIMENTAL
Intervention: Prednisone for 6 weeks followed by 5 million units of recombinant interferon alfa‐2b daily for 16 weeks
Number of subjects: 168
Study: 849691

Group type: EXPERIMENTAL
Intervention: Combined treatment with BCG and chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 31693643

Group type: EXPERIMENTAL
Intervention: Low-volume HIIT (20 min, 2 d/wk)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High-volume HIIT (40 min, 2 d/wk)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Attention Control (AC) group (physical activity recommendations, n = 14)
Number of subjects: 70
Study: 31600397

Group type: EXPERIMENTAL
Intervention: Nivolumab and Bevacizumab
Number of subjects: 38
Study: 28391289

Group type: EXPERIMENTAL
Intervention: Web-delivered sleep intervention (sleep-hygiene education, stimulus control, and cognitive behavioral therapy)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (vascular risk factor education)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Web-delivered sleep intervention
Number of subjects: 134
Study: 25500986

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 78

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 78
Study: 24160217

Group type: EXPERIMENTAL
Intervention: Educational intervention by a health professional
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 107
Study: 21454798

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 and 300 mg once daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 50
Study: 17988832

Group type: EXPERIMENTAL
Intervention: GCBT+EX (Group Cognitive Behavioral Therapy + Exercise)
Number of subjects: 74

Group type: COMPARATOR
Intervention: GCBT+ED (Group Cognitive Behavioral Therapy + Education)
Number of subjects: 74
Study: 17039901

Group type: COMPARATOR
Intervention: Fibrates
Number of subjects: 100

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 100
Study: 14706902

Group type: EXPERIMENTAL
Intervention: Caelyx
Number of subjects: 474

Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 474
Study: 11023504

Group type: EXPERIMENTAL
Intervention: 2‐CdA + prednisone (P)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Chlorambucil (Chl) + prednisone (P)
Number of subjects: 229
Study: 8836985

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg/day) for 8 weeks
Number of subjects: 19
Study: 1466463

Group type: EXPERIMENTAL
Intervention: Epidural lumbar fentanyl
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural thoracic fentanyl
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 50
Study: 6373154

Group type: EXPERIMENTAL
Intervention: Salbutamol (250 micrograms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terbutaline (500 micrograms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aminophylline (250 mg)
Number of subjects: 20
Study: 30770432

Group type: EXPERIMENTAL
Intervention: Preferred algorithm requiring ≥3 MS-related claims from any combination of inpatient, outpatient, or DMT claims within a 1-year time period.
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Preferred algorithm tested in Saskatchewan cohort from the general population.
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Algorithms including DMT claims.
Number of subjects: 4
Study: 29790072

Group type: EXPERIMENTAL
Intervention: Social comparison feedback (e-mailed summary of routine laboratory test ordering vs. service average for the prior week, linked to a personalized dashboard)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Social comparison feedback for physicians whose absolute ordering rate deviated from the peer rate by more than 1.0 laboratory test per patient-day
Number of subjects: 114
Study: 28033279

Group type: EXPERIMENTAL
Intervention: Aneurysm clipping plus fenestration of lamina terminalis (FLT)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Single aneurysm clipping
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Aneurysm clipping plus FLT
Number of subjects: 288
Study: 25296586

Group type: EXPERIMENTAL
Intervention: Diet intervention focused on plant foods with a low glycemic load, low in saturated fats and alcohol, and rich in antioxidants and fiber.
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention based on moderate‐intensity PA.
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Diet + Physical Activity intervention.
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 234
Study: 22373589

Group type: COMPARATOR
Intervention: Group S + S: normal saline 0.15 ml/kg + normal saline 0.06 ml/kg
Number of subjects: 440

Group type: COMPARATOR
Intervention: Group S + M: normal saline 0.15 ml/kg + midazolam 0.06 mg/kg
Number of subjects: 440

Group type: COMPARATOR
Intervention: Group D + S: dexmedetomidine 0.6 μg/kg + normal saline 0.06 ml/kg
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Group D + M: dexmedetomidine 0.6 μg/kg + midazolam 0.06 mg/kg
Number of subjects: 440
Study: 20833658

Group type: EXPERIMENTAL
Intervention: Clonidine-diuretics association
Number of subjects: 270

Group type: COMPARATOR
Intervention: Diuretics alone
Number of subjects: 270
Study: 18821668

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: Calcium (1,000 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vitamin D3 (2,000 IU/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vitamin D3 plus Calcium (1,000 mg/day)
Number of subjects: 18
Study: 15774435

Group type: EXPERIMENTAL
Intervention: Bobath based treatment (BB)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Movement science based treatment (MSB)
Number of subjects: 120
Study: 12444814

Group type: EXPERIMENTAL
Intervention: Venlafaxine (225 to 350 mg/day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Clomipramine (150 to 225 mg/day)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 73
Study: 10343140

Group type: EXPERIMENTAL
Intervention: Intravenous iron saccharate for 8 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Erythropoietin in patients without response after iron treatment
Number of subjects: 20
Study: 8952658

Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no amifostine)
Number of subjects: 0
Study: 1935353

Group type: EXPERIMENTAL
Intervention: Levo-praziquantel (L-PZQ) at 20 mg/kg
Number of subjects: 278

Group type: COMPARATOR
Intervention: Praziquantel (PZQ) at 40 mg/kg
Number of subjects: 278
Study: 6460467

Group type: EXPERIMENTAL
Intervention: Tetrabenazine (maximum dosage of 200 mg per day for three or more weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30488957

Group type: EXPERIMENTAL
Intervention: Respiration Control (RESP)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Applied Tension (AT)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Combination of AT and RESP
Number of subjects: 547

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 547
Study: 29590421

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study: 27299450

Group type: EXPERIMENTAL
Intervention: Local infiltration with ropivacaine, epinephrine, ketorolac, and clonidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24622951

Group type: EXPERIMENTAL
Intervention: Modified Valsalva manoeuvre (VM) with leg elevation and supine posture
Number of subjects: 372

Group type: COMPARATOR
Intervention: Standard Valsalva manoeuvre (VM)
Number of subjects: 372
Study: 23373268

Group type: EXPERIMENTAL
Intervention: High-dose albumin group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose diuretic group
Number of subjects: 0
Study: 20429825

Group type: EXPERIMENTAL
Intervention: 5% lidocaine medicated plaster
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of 5% lidocaine medicated plaster and pregabalin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17647117

Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser (FS) for LASIK
Number of subjects: 485
Study: 15991509

Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 45
Study: 12045777

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine 15 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral mesalamine 800 mg tid
Number of subjects: 30
Study: 10203619

Group type: EXPERIMENTAL
Intervention: Intervention group (received mailed feedback intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (did not receive the intervention)
Number of subjects: 0
Study: 7617534

Group type: EXPERIMENTAL
Intervention: Empirical function for plasma concentration convolved with a monoexponential function to generate effect site concentration.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effect site concentration and time as independent variables in the model for logit of probability of specific PR score pre-remedication.
Number of subjects: 0
Study: 2217349

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg per day (first 10 days)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo (next 25 days)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo (three tablets per day for one week)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Treatment in the morning, noon, or evening (subsequent weeks)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: No medication (after 10 years of treatment)
Number of subjects: 1
Study: 389262

Group type: EXPERIMENTAL
Intervention: Cremophor
Number of subjects: 104

Group type: COMPARATOR
Intervention: Propylene glycol
Number of subjects: 104
Study: 31558730

Group type: EXPERIMENTAL
Intervention: Extended sleep condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short sleep condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention lapses after either sleep manipulation
Number of subjects: 0
Study: 28875459

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol 100 µg/62.5 µg/25 µg
Number of subjects: 1810

Group type: COMPARATOR
Intervention: Budesonide/formoterol 400 µg/12 µg
Number of subjects: 1810
Study: 26195173

Group type: EXPERIMENTAL
Intervention: Web-based decision support tool
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 125
Study: 22750997

Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Palifermin in TBI recipients
Number of subjects: 251
Study: 20440568

Group type: EXPERIMENTAL
Intervention: Methylphenidate (48-hour on-off medication protocol)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ADHD children (on medication)
Number of subjects: 28

Group type: COMPARATOR
Intervention: ADHD children and control children
Number of subjects: 28
Study: 19587265

Group type: EXPERIMENTAL
Intervention: OXT (1 pmol/kg per min over 90 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16924215

Group type: EXPERIMENTAL
Intervention: Multifactorial back education program
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 193
Study: 14989751

Group type: EXPERIMENTAL
Intervention: Cu-NiTi archwires with a transition temperature of 40 degrees C
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cu-NiTi archwires with a transition temperature of 27 degrees C
Number of subjects: 15
Study: 11350752

Group type: EXPERIMENTAL
Intervention: Antioxidants (500 mg of vitamin C and 400 mg of vitamin E)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 20
Study: 10997544

Group type: EXPERIMENTAL
Intervention: Vitamin A/beta-carotene supplementation
Number of subjects: 10422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10422

Group type: EXPERIMENTAL
Intervention: Night blindness
Number of subjects: 10422
Study: 9036201

Group type: EXPERIMENTAL
Intervention: chronotherapy with heparin and curantyl added to traditional therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: traditional therapy
Number of subjects: 112
Study: 1321177

Group type: EXPERIMENTAL
Intervention: First-hour skin chamber fluids (CF) from antigen challenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-hour buffer-site CF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buffered saline
Number of subjects: 0
Study: 6383790

Group type: EXPERIMENTAL
Intervention: Progabide (19.3‐36 mg/kg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30900408

Group type: EXPERIMENTAL
Intervention: PAT+Lifestyle
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard PAT
Number of subjects: 185
Study: 30268966

Group type: EXPERIMENTAL
Intervention: Low-load resistance training with blood flow restriction (LLRT-BFR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-load resistance training (LLRT)
Number of subjects: 40
Study: 27342914

Group type: EXPERIMENTAL
Intervention: Reduced-dose 2007 Southern Hemisphere trivalent inactivated influenza vaccine formulated with Advax™ delta inulin adjuvant (LTIV+Adj)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Full-dose standard TIV vaccine (no adjuvant)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Reduced-dose TIV vaccine containing Advax adjuvant
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard TIV vaccine
Number of subjects: 100
Study: 24676998

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) 25-150 mg eq. injected intramuscularly in deltoid muscle
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) 25-150 mg eq. injected intramuscularly in gluteal muscle
Number of subjects: 201
Study: 22490266

Group type: EXPERIMENTAL
Intervention: Therapeutic assertive community treatment (ACT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study: 19808912

Group type: EXPERIMENTAL
Intervention: Sativex
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (Sativex and Placebo)
Number of subjects: 30
Study: 17400681

Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BPAP) for 3 months, daily use of 4.8 +/- 0.3 hours
Number of subjects: 52

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 52
Study: 15588555

Group type: EXPERIMENTAL
Intervention: 100 mg oral Minocin MR (minocycline) once daily (o.d.)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Combined erythromycin (2% erythromycin) and benzoyl peroxide (5% benzoyl peroxide) formulation
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: 500 mg oral oxytetracycline (b.d.)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Topical Benzamycin (3% erythromycin + 5% benzoyl peroxide)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Topical Panoxyl Aquagel (5% benzoyl peroxide)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Topical erythromycin-containing regimens
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (minocycline and oxytetracycline)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Topical treatments (particularly benzoyl peroxide)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Active comparator group (topical Panoxyl Aquagel + oral placebo)
Number of subjects: 649
Study: 11887546

Group type: EXPERIMENTAL
Intervention: Nalmefene, 20 micrograms intravenously
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 60
Study: 9707874

Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin A orally (Experimental)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 100
Study: 8550863

Group type: EXPERIMENTAL
Intervention: 25% tetracycline HCl from poly(D,L-lactide/glycolide) film strips (25 TTC-PLGA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control strips without TTC (PLGA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 10
Study: 2136818

Group type: COMPARATOR
Intervention: GR32191 0.125 mg/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: GR32191 0.25 mg/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: GR32191 0.5 mg/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: GR32191 1.0 mg/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: GR32191 17.5 mg, three times daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: GR32191 17.5 mg, every 12 hours
Number of subjects: 13

Group type: COMPARATOR
Intervention: GR32191
Number of subjects: 13
Study: 30311402

Group type: EXPERIMENTAL
Intervention: Short-acting insulin (insulin lispro) at 30°C and 10% humidity
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Short-acting insulin (insulin lispro) at 15°C and 10% humidity
Number of subjects: 10
Study: 28108426

Group type: EXPERIMENTAL
Intervention: Surgical intervention (CSDH evacuation)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nonsurgical management (spontaneous resolution)
Number of subjects: 45
Study: 26122122

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23748324

Group type: EXPERIMENTAL
Intervention: TiUnite implants
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Machined implants
Number of subjects: 44
Study: 21801549

Group type: EXPERIMENTAL
Intervention: Consultation with GP after invitation
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Consultation about child's weight
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Referral to specialist clinic
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Alternative weight-management referral
Number of subjects: 285
Study: 19427979

Group type: EXPERIMENTAL
Intervention: Paired cardiac CT scans
Number of subjects: 6814

Group type: COMPARATOR
Intervention: Electron beam CT (EBCT)
Number of subjects: 6814

Group type: EXPERIMENTAL
Intervention: MDCT cardiac scans
Number of subjects: 6814
Study: 16886317

Group type: EXPERIMENTAL
Intervention: Self-brushing by test subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teeth brushed by a dental hygienist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of dentifrice
Number of subjects: 0
Study: 14742390

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (1 mg/kg) under propofol anesthesia (PROP-F)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (1 mg/kg) under isoflurane anesthesia (ISO-F)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline (0.1 mL/kg) under propofol anesthesia (PROP-S)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline (0.1 mL/kg) under isoflurane anesthesia (ISO-S)
Number of subjects: 48
Study: 11585482

Group type: EXPERIMENTAL
Intervention: Michigan's GDL program (implemented April 1, 1997)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Michigan's GDL program
Number of subjects: 0
Study: 9422896

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 12
Study: 8373897

Group type: EXPERIMENTAL
Intervention: Blood samples from central catheters (internal jugular, caval, Shaldon, pulmonary artery)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Blood samples from internal jugular catheters
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Blood samples from Shaldon catheters
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Blood samples from peripheral venous cannulas
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blood samples from venipunctures
Number of subjects: 60
Study: 3602098

Group type: EXPERIMENTAL
Intervention: Static visual fixations
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Saccadic eye movements
Number of subjects: 35

Group type: COMPARATOR
Intervention: Smooth pursuit eye movements
Number of subjects: 35